Send to

Choose Destination
See comment in PubMed Commons below
J Clin Psychiatry. 2007;68 Suppl 8:35-41.

Revisiting monoamine oxidase inhibitors.

Author information

Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA.


Monoamine oxidase inhibitors (MAOIs) were among the first class of agents introduced for the treatment of depression. However, they have fallen out of favor among clinicians over the years, due mostly to an unfavorable safety profile, the need for restrictive dietary prohibitions, and the fear of hypertensive crisis. The development of a novel, transdermal MAOI system now offers clinicians an additional option for managing patients with unipolar, bipolar, atypical, and treatment-resistant depression.

[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Physicians Postgraduate Press, Inc.
    Loading ...
    Support Center